成都先衍生物技术

Xianyan Biotech is a clinical-stage biotechnology company based in Chengdu, China, specializing in the discovery and development of RNA interference (RNAi) therapeutics. The company has established a robust technology platform for small interfering RNA (siRNA) drugs, focusing on both GalNAc-mediated liver targeting and innovative extrahepatic delivery systems. Its lead program, XY-001, is a long-acting siRNA targeting PCSK9 for hypercholesterolemia, which has entered Phase 1 clinical trials. The pipeline also includes candidates for hypertension, thrombosis, and other metabolic disorders, aiming to provide potent and durable treatment options with low-frequency dosing. Xianyan Biotech is led by a team of experts in oligonucleotide chemistry and is backed by leading healthcare investors.